

Background

We recently presented the feasibility of single circulating tumor cell (CTC) analysis using the QIAseq single cell isolation platform (Fig. A, QIAGEN, Germany), followed by whole transcriptome amplification (WTA) and targeted Next Generation Sequencing (NGS).

Alternatively to the previously used single cell WTA – workflow, we here applied the QIAseq UPX 3' Transcriptome Kit (UPX) for high throughput gene expression analysis for single cell CTC analysis from blood samples of patients (pts) with metastatic breast cancer (MBC) and primary ovarian cancer (POC). This workflow has the advantage of better confirming the sequencing results using unique molecular identifiers (UMI).




Fig. A: Array. Tumor cell surrounded by beads (20x magnification; 40x magnification).




Fig. C: Workflow for single cell isolation.

Updated Methods






Fig. E: The workflow of the QIAseq UPX 3' Transcriptome Kit



Experimental design (Fig. D):

CTCs were isolated from 5 ml whole blood of 9 MBC, 2 POC pts and 2 healthy donors (HD) using positive immunomagnetic selection (AdnaTest EMT-2/StemCellSelect™) followed by QIAseq single cell isolation. Adhesion of CTCs to the QIAseq array microrafts was supported by pre-treating the array with Corning® Cell-Tak™ Adhesive. Using an inverted microscope, single cells were mechanically isolated by picking out one of the 12000 microrafts. Subsequently, mRNA of single cells was amplified by WTA (REPLI-g WTA Single Cell Kit, QIAGEN) and cDNA of the cells was further analyzed by targeted NGS using a QIAseq™ Targeted RNA Panel (Human Cancer Transcriptome Panel, 395 genes) (Single cells [AdnaTestSelect-QIAseq-WTA-workflow]; n= 7 MBC) (data not shown). QIAseq further allowed modified single cells analysis with the QIAseq UPX 3' Transcriptome Kit, followed by whole transcriptome NGS (Single cells [AdnaTestSelect-QIAseq-UPX-workflow]; n= 2 MBC, n= 2 POC pts & n= 2 healthy donors). Methods were validated in spike-in experiments using different cell lines spiked into blood of healthy donors

Results



Conclusion

The workflow evaluation with the QIAseq in CTC analysis shows:

- the feasibility of the new AdnaTestSelect-QIAseq-UPX-workflow.
- that the QIAseq single cell isolation platform allows subsequent transcriptome analysis followed by NGS to get insights into single cell heterogeneity for further therapeutic strategies.
- that using the combination of AdnaTestSelect & QIAseq shows an overall single cell recovery >50 %.
- both described workflows have to be further evaluated in more detail.
- a pending analysis of the comparison of these UPX results to traditional WTA.